Revance Therapeutics gains as Crown Labs further extends tender offer

Revance Therapeutics ( NASDAQ: RVNC ) rose 2.4% in after hours trading after Crown Laboratories extended its tender offer by another week. The tender offer is extended until Nov.

26, according to an 8-K filing on Tuesday. Revance reiterated that its ongoing discussions with Crown.